Skip to main content
Haisco Pharmaceutical Group Co.,Ltd logo

Haisco Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 002653 ISIN · CNE100001BC7 LEI · 300300GRLH34A8GPJ639 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,439 across all filing types
Latest filing 2025-04-24 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002653

About Haisco Pharmaceutical Group Co.,Ltd

https://www.haisco.com

Haisco Pharmaceutical Group Co.,Ltd. focuses on the research, development, production, and commercialization of innovative drugs and high-end generic pharmaceuticals. The company maintains a specialized portfolio across therapeutic areas including anesthesia, parenteral nutrition, anti-infection, cardiovascular health, and endocrine disorders. Key products include advanced anesthetic agents and specialized nutritional injections designed for clinical use. Haisco prioritizes technological innovation through a dedicated R&D infrastructure, targeting the development of small molecule chemical drugs and complex delivery systems. Its operations emphasize high-standard manufacturing processes and the integration of clinical research to address complex medical requirements. The company aims to provide therapeutic solutions that enhance patient care through a commitment to scientific excellence and product quality.

Recent filings

Filing Released Lang Actions
关于应收款项合并报表范围内关联方组合计提坏账准备的会计估计变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from the board of directors of 海思科医药集团股份有限公司 regarding a change in accounting estimates related to bad debt provisions for intercompany receivables within the consolidated financial statements. It details the nature of the accounting estimate change, the reasons, and the approvals from the board, audit committee, and supervisory board. The document does not contain actual financial statements or substantive financial data but is a formal announcement of an accounting policy change. It is not a full annual or interim report, audit report, or earnings release. Given the nature of the content and the formal announcement style, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-04-24 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 27th meeting of the 5th Board of Directors of 海思科医药集团股份有限公司. It includes voting results on various proposals such as approval of the 2025 Q1 report, amendments to the company bylaws, and revisions to multiple governance and management systems. The document also references that some proposals require shareholder approval and points to other announcements for further details. The content focuses on board decisions, governance changes, and management system updates rather than presenting financial statements or full reports. The document length is 3486 characters, which is relatively short and more consistent with a board meeting resolution announcement rather than a full report. Therefore, the most appropriate classification is Board/Management Information (MANG).
2025-04-24 Chinese
债务融资工具信息披露事务管理制度
Governance Information Classification · 95% confidence The document is titled as a "Debt Financing Instrument Information Disclosure Management System" issued by a company, detailing the internal rules, procedures, and responsibilities for information disclosure related to debt financing instruments. It references regulatory frameworks from the People's Bank of China and the China Interbank Market Dealers Association, and outlines the company's governance and compliance measures for disclosure. The content is focused on governance and management of disclosure processes rather than presenting financial data, audit results, or financial statements. It is a governance-related document describing internal rules and procedures for disclosure management, not a financial report or announcement. Therefore, the document best fits the category of Governance Information (CGR).
2025-04-24 Chinese
董事会提名委员会工作制度
Governance Information Classification · 95% confidence The document is titled as the 'Board Nomination Committee Working System' of a company, detailing the structure, responsibilities, and procedures of the board nomination committee. It focuses on governance practices, committee composition, decision-making processes, and related rules. There is no financial data, earnings information, or regulatory filing content. The document is a governance-related internal policy or procedural document. Therefore, it fits best under Governance Information (CGR). The document length is 2095 characters, which is relatively short but contains substantive governance content, not just an announcement or summary.
2025-04-24 Chinese
募集资金管理制度
Governance Information Classification · 95% confidence The document is a detailed internal policy titled "募集资金管理制度" (Fundraising Capital Management System) of 海思科医药集团股份有限公司. It outlines the rules, procedures, and governance related to the management, use, supervision, and reporting of funds raised by the company through securities issuance. The content includes regulatory references, internal controls, approval processes, and disclosure obligations related to fundraising capital. It is not a financial report, earnings release, or announcement but a governance and compliance document detailing internal rules and procedures for managing raised capital. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-04-24 Chinese
信息披露事务管理制度
Governance Information Classification · 95% confidence The document is a detailed information disclosure management system of a company, outlining the rules, standards, and procedures for information disclosure including periodic reports (annual, interim, quarterly), temporary reports, major events, and other regulatory compliance matters. It references regulatory bodies such as the China Securities Regulatory Commission (CSRC) and Shenzhen Stock Exchange, and discusses the preparation and disclosure of annual reports, interim reports, quarterly reports, audit reports, and other filings. The document is a governance and procedural manual rather than an actual financial report or announcement. It does not contain financial data or results but rather prescribes how such information should be disclosed. Therefore, it fits best under Governance Information (CGR), which covers internal rules, board structure, and governance practices related to disclosures.
2025-04-24 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.